Market Overview

UPDATE: Deutsche Bank Upgrades IPC The Hospitalist Company to Buy on Good Growth Prospects


In a report published Thursday, Deutsche Bank analyst Darren Lehrich upgraded the rating on IPC The Hospitalist Company (NASDAQ: IPCM) from Hold to Buy, and raised the price target from $36.00 to $48.00.

In the report, Lehrich noted, “IPCM continues to churn out strong growth, and the valuation multiples we've been using in our PT have been too stingy in the context of this company's near-term and longer-term growth prospects. We're moving off our 9x EV/EBITDA / 16x P/E targets and taking them to 10x and 18.5x, respectively. These targets are more in-line with the physician management group's recent averages, and reflect our view that IPCM's ability to sustain mid/high-teens earnings growth looks pretty solid in light of its hiring and productivity metrics, M&A prospects and untapped opportunities in the post-acute arena.”

IPC The Hospitalist Company closed on Wednesday at $39.82.

Latest Ratings for IPCM

Aug 2015JefferiesDowngradesBuyHold
Aug 2015DoughertyDowngradesNeutralSell
Aug 2015William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for IPCM
View the Latest Analyst Ratings


Related Articles (IPCM)

View Comments and Join the Discussion!

Posted-In: Deutsche BankAnalyst Color Upgrades Analyst Ratings

Latest Ratings

MRSNSVB LeerinkReiterates21.0
CTASB of A SecuritiesDowngrades
VICRBWS FinancialInitiates Coverage On84.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at